Editorial: Neuroinflammation in acquired epilepsy

Abstract

In spite of astonishing advances in epilepsy research and treatment over the past few decades, epilepsy remains one of the most common and devastating brain diseases and still affects approximately 65 million people globally In addition to their wide-ranging side effects, antiseizure drugs (ASDs) are not effective in controlling seizures in more than 30% of patients who have pharmacoresistant epilepsy It is rather unfortunate that current medications provide merely symptomatic relief and have not been demonstrated to prevent epilepsy in people at risk or modify the disease progression Therefore, there remains an urgent need for alternative antiepileptic treatments, despite the rapid expansion of modern ASDs that emerged during the first 2 decades of this century

Topics & Concepts